COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Inc. announces extension of conditional approval by FDA for Canalevia®-CA1 drug for chemotherapy-induced diarrhea in dogs and seeks partners for NP300 prescription drug for general diarrhea in dogs at Pet Connect conference -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
Jaguar Health, Inc. to present at NobleCon20 and Emerging Growth Conference. Lisa Conte to present on December 3 and virtually on December 5, 2024. Jaguar focuses on gastrointestinal distress medicines -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health, Inc. announces extension of FDA approval for Canalevia®-CA1 for chemotherapy-induced diarrhea in dogs, seeks partner for NP300 development at Pet Connect conference
